Itulazax (Betula Verrucosa (108))

Betula verrucosa in Itulazax provides repeated low‑dose exposure to the birch pollen allergen via the sublingual route. This exposure shifts the immune response from an IgE‑driven pathway toward a regulatory phenotype, increasing allergen‑specific IgG4 and regulatory T‑cell activity, which together diminish allergic inflammation and symptom severity.

The dosage regimen for Itulazax is determined individually by a qualified healthcare professional based on the patient’s sensitivity, age, and clinical response. Prescribers follow established sublingual immunotherapy protocols and adjust the dose according to tolerance and therapeutic goals.

Safety data for Itulazax in pregnancy and lactation are limited. It should only be prescribed when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a obstetrician or specialist.

To request Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Itulazax offers a sublingual route, allowing home‑based administration under medical supervision, whereas many alternatives are subcutaneous injections requiring clinic visits. Both approaches aim to induce tolerance, but sublingual therapy may have a lower risk of systemic reactions and greater patient convenience, though individual response varies.

Itulazax should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency. Do not refrigerate unless specifically instructed on the label.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it for the recommended time before swallowing, typically without water. Initial doses are given under medical supervision to monitor for any immediate reactions.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe asthma exacerbations, and rare cardiovascular events like hypotension. Patients should be observed after the first dose and instructed to seek emergency care if they experience symptoms such as difficulty breathing, swelling of the throat, or a rapid drop in blood pressure.

Itulazax is contraindicated in individuals with a history of severe systemic reactions to birch pollen extracts, uncontrolled asthma, or those receiving beta‑blocker therapy that could mask anaphylaxis. It should also be avoided in patients with known hypersensitivity to any component of the formulation.